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A B S T R A C T
Purpose: The comorbidity of depression in patients with epilepsy is common and treatment is still
controversial. This pilot study was aimed at evaluating the efﬁcacy and safety of Xylaria nigripes for
treating depressive symptoms in patients with epilepsy during 12 weeks of treatment.
Methods: A multicenter, double-blind, placebo-controlled, randomized superiority study was
performed. A total of 104 patients with epilepsy who fulﬁlled the study criteria were randomized
1:1 to receive Xylaria nigripes (the Wu Ling group) or placebo (the placebo group) treatment in the 12-
week period of study. The participants were visited on weeks 0, 2, 4, 8, and 12 of the treatment course.
Results: Eighty-one patients ﬁnished all of the visits. The primary efﬁcacy endpoint in this study was the
total effective rate for depression, which was signiﬁcantly greater in the Wu Ling group (51.3%, n = 39)
than in the placebo group (35.7%, n = 42, 0.51–0.36 = 0.15, 95% CI 0.06 to 0.37, U = 2.83, P = 0.002) after
12 weeks of treatment. No differences in seizure frequency or changes in severity were found between
the Wu Ling and the placebo groups. In addition, the quality of life and seizure worry subscale scores in
patients with epilepsy were also improved more notably in the Wu Ling group than in the placebo group
(P < 0.05). Most of the adverse effects (AEs) in this study were mild and had no differences between the
Wu Ling and the placebo groups.
Conclusion: Xylaria nigripes could alleviate depressive symptoms within 12 weeks treatment and was
well tolerated in patients with epilepsy.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Depression is the most frequently occurring psychiatric
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quality of life in patients with epilepsy [3], and is associated with a
poor response to pharmacological and surgical treatments of
epileptic disorders [4,5].
However, depressive symptoms in epilepsy have not been fully
recognized by neurologists. The treatment for comorbid depres-
sion in patients with epilepsy is also challenging. Some reports of
pharmaceutical and psychotherapeutic approaches for depressive
symptoms in patients with epilepsy are open-labeled [6–9]. The
safety of selective serotonin reuptake inhibitor (SSRI) antidepres-
sants in patients with epilepsy is still controversial. Although someserved.
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frequency [10,11], others indicated that SSRIs could exacerbate
seizures by lowering the seizure threshold or by interacting with
antiepileptic drugs (AEDs) [12,13], especially when taken in
overdose [14,15]. There have been no guidelines, expert consensus
or recommendations for the treatment of comorbidity of depres-
sion in patients with epilepsy until now. Randomized clinical trials
and new therapies are urgently needed.
Xylaria nigripes (also referred to as Wu Ling Shen) is a
traditional Chinese medicine which belongs to the Xylariaceae
family of fungi. It grows several feet underground in the fungus
combs of the Odontotermes termite species during the spring and
summer seasons, and contains many bioactive molecules such as
glycosides, steroids and amino acids [16,17]. Studies demonstrated
Xylaria nigripes had antidepressant and sleep-regulating effects,
and was used to treat depression and insomnia in clinical practice
[18,19]. In a multicenter randomized double-blind parallel study,
Xylaria nigripes (under the brand name ‘Wu Ling Capsule’) had a
similar effect to Deanxit to alleviate depressive, anxiety and
insomia symptoms in patients with depression [20]. In animal
studies, Xylaria nigripes was found to prolong the latency of
convulsive seizure and delay the kindling process in penty1enete-
trazol induced rat epilepsy models [21]. The pharmacological
mechanisms of Xylaria nigripes appeared to be complicated. As
indicated by Ma et al. [22], Xylaria nigripes promoted the activity
of glutamate decarboxylase and the combination of g-aminobu-
tyric acid (GABA) with GABA receptors. It also had anti-oxidative
and anti-inﬂammatory effects [23–25]. In this study, therefore, we
used Xylaria nigripes as an anti-depressive therapy in patients
with comorbidity of epilepsy and depression to evaluate its effects
on depression and safety for seizures.
The primary objective of this study was to evaluate the efﬁcacy
of Xylaria nigripes on depressive symptoms in patients with
epilepsy during 12 weeks of treatment. The secondary objectives
included two aspects: (1) assessing the inﬂuences of Xylaria
nigripes on seizure frequency, seizure severity, sleep quality and
quality of life for patients with epilepsy; (2) evaluating the safety of
Xylaria nigripes in patients with epilepsy.
2. Methods
2.1. Study design
This study (temporarily referred to as WL-2010) was a
multicenter, double-blind, randomized, placebo-controlled, supe-
riority clinical trial. The patients in this study were randomized 1:1
to receive Xylaria nigripes (the Wu Ling group) or a placebo (the
Placebo group) for 12 weeks.
For the primary endpoint, the total effective rate for depressive
symptoms in patients with epilepsy was compared between the
Wu Ling and the Placebo groups at the end of 12 weeks’ treatment.
The sample size was determined to be about 100 cases for each
group by the statistical calculation formula, using at least 10%
difference of the total effective rate for depression between the Wu
Ling and the Placebo groups. Randomization was performed
centrally by the Clinical Research Organization (CRO). The random
numbers were generated using the PROC PLAN process of the SAS
9.2 software. Randomization lists were assigned to every study
center. Investigators and participants were all blinded to the
assignment. The Wu Ling Capsule and the placebo could not be
differentiated from appearance.
All of the measurement scales in this study, including the
Hamilton Depression Rating Scale (HAMD), the National Hospital
Seizure Severity Scale (NHS3), the Pittsburgh Sleep Quality Index
(PSQI), and the Quality of Life in Epilepsy Inventory (QOLIE-31)
were evaluated in each center by one or two neurological doctorswho had been trained in advance and whose evaluations were
found to be in good agreement.
The protocol of the trial was approved by the local independent
ethics committees of all the participating hospitals. All the patients
recruited had to agree with and sign a written informed consent
prior to entering the study. This study had been registered at the
ClinicalTrial.gov system of the U.S. National Institutes of Health
and the Identiﬁer was NCT01125241.
2.2. Patients
The patients were recruited from the epileptic clinics of nine
hospitals located in Shanghai, Hangzhou, Guangzhou and Beijing.
Patients were enrolled if they consented to participate in the study
and met the following inclusion criteria: (1) older than or equal to
18 years of age (no gender limitation); (2) a diagnosis of epilepsy
based on clinical data and EEG recording, and having had regular
treatment with AEDs for at least 6 months, without recent
adjustments to medication, in order to avoid the confounding effects
of AEDs adjustment; (3) at least 24 h from the last seizure before
accepting psychological evaluation to avoid the effect of postictal
state; (4) having a HAMD score of greater than or equal to 17; (5) not
taking any antidepressants or antipsychotics in the previous 2 weeks.
The exclusion criteria included the following: (1) having a
history of psychiatric symptoms other than depression; (2) having
a history of suicidal thoughts or suicidal behaviors; (3) having
severe cognitive impairment, chronic organic failures or malignant
tumors; (4) liver function tests indicating alanine aminotransfer-
ase (ALT) or aspartate aminotransferase (AST) higher than 1.5 times
the normal reference value, or a white blood count of less than
2500/ml, or a neutrophils count of less than 1000/ml; (5) being
pregnant or lactating.
The patients were fully informed of the beneﬁts and risks of
entering this study. They had the right to drop out the study at any
time if they felt no improvement of depression or experienced
exacerbation of seizures. They would be recommended to visit a
psychiatrist if they had suicidal thoughts or had very severe
depressive symptoms. If they improved markedly and wanted to
continue taking the medicine, they would receive another extra free
supply of the Wu Ling Capsule for 3 months after ending the study.
This extra period of taking the Wu Ling Capsule was also monitored.
2.3. Study endpoints
The efﬁcacy of Xylaria nigripes on depression in patients with
epilepsy was evaluated by the HAMD reductive rate. As ﬁrstly
recommended by Snaith et al. [26], the HAMD scale has become a
common tool to assess severity of depressive symptoms and the
efﬁcacy of treatment [27]. The HAMD reductive rate is calculated
as: (score before treatment  score after treatment)/score before
treatment  100%. There are four levels of efﬁcacy based on the
HAMD reductive rate: 75% means clinical recovery, 50–74%
means signiﬁcantly improved, 25–49% means slightly improved,
and <25% means ineffectiveness. The total effective rate for
depression is calculated as: (clinical recovery rate + signiﬁcantly
improved rate)/n. The primary efﬁcacy endpoint was to evaluate
the total effective rate for depression in patients with epilepsy. The
secondary efﬁcacy endpoints included changes in seizure frequen-
cy, seizure severity (the NHS3 score), sleep quality (the PSQI score)
and quality of life (the QOLIE score). Adverse events (AEs),
laboratory data and vital signs were analyzed as safety variables.
2.4. Study procedures
The Wu Ling Capsule and the placebo were both produced by
Zhejiang Jolly Pharmaceutical Limited Corporation (Hangzhou,
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were assigned to a parallel group and administered with the Wu
Ling Capsule or the placebo orally at a dose of three tablets (each
containing 0.33 g of the drug or placebo powder) three times daily
for 12 weeks.
The participants were regularly visited at weeks 0, 2, 4, 8, and
12 of the treatment course. Demographic, seizure-related and
medication data were collected before initiation of the treatment.
The seizures were diagnosed and classiﬁed according to the
International League Against Epilepsy (ILAE 1981) classiﬁcation of
epileptic seizures.
The severity of depression was assessed by using the 17-item
Hamilton Depression Rating Scale (HAMD) in weeks 0, 2, 4, 8 and
12 of the treatment period. The Chinese version of HAMD has been
tested and proved to have good validity and reliability [28].
The PSQI was used to evaluate the sleep quality of patients in
weeks 0, 4, 8 and 12. The PSQI scale evaluates seven aspects of
sleep quality including subjective sleep quality, sleep latency, sleep
duration, habitual sleep efﬁciency, sleep disruption, use of sleeping
medication, and daytime dysfunction. The total PSQI score is
positively correlated with sleep disturbance and a score of 8
suggests bad sleep quality [29].
QOLIE-31 was assessed in weeks 0 and 12 of the treatment
period. Seven subscales are included in QOLIE-31: overall quality of
life, seizure worry, emotional well-being, energy/fatigue, cognitive
function, medication effects and social function. A high QOLIE-31
score indicates a good quality of life [30].
Diaries to record seizures were given to every patient at the
initiation of treatment. The R ratio is the ratio of change in
seizure frequency to the sum of baseline and ﬁnal seizure
frequencies. The R ratio is calculated as: (ﬁnal  baseline)/
(ﬁnal + baseline). The value of R lies between 1 to +1, and 0.33
equates to a 50% reduction in seizure frequency [31]. The severity
of seizures in patients with epilepsy in the previous 3 months
was evaluated by using NHS3 in weeks 0 and 12 of the treatment
period [32].
Vital signs, including heart rate and blood pressure, and adverse
events were monitored during the whole treatment period.
Regular blood and urine tests, liver and renal function tests,
electrocardiogram (ECG) and electroencephalogram (EEG) were
carried out before the initiation and at the end of treatment. The
abnormal rate of EEG was regarded as a parameter of evaluating
seizure aggravation.
2.5. Statistical analyses
All statistical analyses were performed using SAS 9.2 software.
The superiority trial employed statistical methods which were
used to judge whether the improvement of depressive symptoms
in the Wu Ling group was better than in the placebo group. Data
analyzed in this study were from the per-protocol population.
Quantitative variables are presented in the format ‘‘mean  stan-
standard deviation (SD)’’. Categorical variables are described by
frequency and percentage. Hypothesis testing on comparisons
between groups were carried out with an a-level of 0.05 and were
two-sided. An independent t-test or Chi-square test was used when
data conformed to a normal distribution; otherwise the Wilcoxon
rank sum test was used. The comparisons of efﬁcacy parameters
between groups were conducted after adjusting for the effects of
different study centers. A superiority test was performed to test the
difference in total effective rate for depression between groups,
using the following formula: u = [(PT  PC)  d0]/SPT-PC (set
pT  pC > d = 0.10). AEs are summarized for both groups and
presented as the percentage of subjects having an event, which
was compared between the Wu Ling and the Placebo groups using a
Chi-square test.3. Results
3.1. Description of patients
The recruitment period was from November 2010 to August
2013. The study ended before the target sample size was reached
because the HAMD scores of many patients screened were less
than 17 points, the process of recruiting was slow and the
guarantee period of the study drug had expired.
By the end of the recruitment period, a total of 144 patients
were screened, of which 104 patients fulﬁlled the study criteria
and were included in this study. Forty patients were excluded for
the following reasons: HAMD score <17 (30/40), elevated liver
enzymes (2/40), not willing to enter study (5/40), and adverse
effects of AEDs (3/40). The included patients were randomized to
form a baseline before starting treatment. Four patients did not
take the medicine after randomization and were excluded from the
analysis. Therefore, the number of cases meeting per-protocol
population and included in the analysis was 100. Ten patients
dropped out in week 4, six patients in week 8, and one patient in
week 12. The reasons for dropout were mostly withdrawal of
consent (11 patients), and some were due to adverse events
(4 patients) or loss of contact (1 patient). One patient dropped out
because of an attack of SE, but she was veriﬁed to be in the placebo
group after urgently unblinding (see Fig. 1).
As shown in Table 1, almost all of the demographic and seizure-
related variables had no differences between the Wu Ling group
(n = 51) and the Placebo group (n = 49) at baseline. The AEDs taken
in this study were carbamazepine (CBZ), valproate (VPA),
topiramate (TPM), oxcarbazepine (OXC), lamotrigine (LTG),
levetiracetam (LEV), phenobarbital (PB), phenytoin (PHT), and
clonazepam (CZP). There were no signiﬁcant differences in the
percentages of patients taking each kind of AED in the Wu Ling and
the Placebo groups (see Table 1). The HAMD, PSQI and QOLIE-31
total scores and their subscale scores all showed no differences
between the Wu Ling and the Placebo groups (P > 0.05). The total
HAMD score ranging from 17 to 24 is regarded as an indicator of
moderate depression which indicates severe depression when
greater than 24. Patients with moderate depression dominated
both the Wu Ling and the Placebo groups, at levels of 92.2% and
95.9%, respectively. The percentages of patients with bad sleep
quality (PSQI score  8) were also similar in the Wu Ling and the
Placebo groups, at 66.7% and 69.4%, respectively.
3.2. Efﬁcacy of Wu Ling Capsule on depressive symptoms in patients
with comorbidity of epilepsy and depression
The total effective rate for depression in weeks 2, 4, 8 and
12 was compared between the Wu Ling and the Placebo groups
using superiority testing and adjusting for the effects of different
centers. The results show that the total effective rate for depression
in week 12 was signiﬁcantly greater in the Wu Ling group (51.3%,
n = 39) than in the Placebo group (35.7%, n = 42, 0.51–0.36 = 0.15,
95% CI 0.06 to 0.37, U = 2.83, P = 0.002), but there were no
differences in week 2 (4.0% vs. 14.6%), 4 (23.3% vs. 22.2%) and 8
(35.9% vs. 34.9%) between the Wu Ling and the Placebo groups (see
Fig. 2a). The total HAMD score at baseline showed no difference
between the Wu Ling and the Placebo groups. The total HAMD
scores and the differences in the HAMD scores before and after
treatment (DHST) in weeks 2, 4, 8 and 12 were also compared
between the Wu Ling and the Placebo groups. The results showed
that in week 12 the total HAMD score (9.9  5.2 vs. 12.1  5.3,
Z = 2.088, P = 0.0367) was signiﬁcantly lower in the Wu Ling group
than in the Placebo group, while the DHST (10.3  4.69 vs. 6.9  4.34,
10.3–6.9 = 3.4, 95% CI 1.38–5.38, t = 3.37, P = 0.001) was signiﬁcantly
greater in the Wu Ling group than in the Placebo group. There were no
Fig. 1. Flow chart of enrollment and follow-up of patients.
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8 between the Wu Ling and the Placebo groups (see Fig. 2b and c).
3.3. Effects of Wu Ling Capsule on R ratio and NHS3 score in patients
with comorbidity of epilepsy and depression
The R ratio and NHS3 score which represented changes in
seizure frequency and severity before and after 12 weeks’
treatment were compared for the Wu Ling and the Placebo groups.
As shown in Table 2, the R ratio, the NHS3 score at baseline, the
NHS3 score at the end of treatment and the difference in NHS3 score
before and after 12 weeks of treatment all showed no differences
between the Wu Ling and the Placebo groups (P > 0.05, see Table 2).
3.4. Effects of Wu Ling Capsule on sleep quality and quality of life in
patients with comorbidity of epilepsy and depression
The PSQI score at baseline and in weeks 4, 8 and 12 of the
follow-up visits, and the difference in PSQI score before and after
treatment were all compared for the Wu Ling and the Placebo
groups. The results show that the PSQI score was slightly lower and
the difference in the PSQI score before and after treatment was
slightly greater in week 12 in the Wu Ling group than in thePlacebo group (5.9  3.5 vs. 7.6  4.0, Z = 1.904, P = 0.0568 and
3.5  4.12 vs. 1.9  3.65, t = 1.84, P = 0.070 respectively), but these
differences were not statistically signiﬁcant. There were also no
differences in PSQI score and in the change in PSQI score before and
after treatment in weeks 4 and 8 follow-up visits, between the Wu
Ling and the Placebo groups.
The total QOLIE-31 score and the seven subscales scores of the
Wu Ling and the Placebo groups were also compared. There were
no differences in the QOLIE-31 total score and the seven subscales
scores between the Wu Ling and the Placebo groups at baseline.
The differences in the total QOLIE-31 score (6.9  9.2 vs.
2.5  7.0, t = 2.37, P = 0.020), the overall quality of life score
(6.5  8.5 vs. 1.9  6.3, t = 2.75, P = 0.008) and the seizure worry
score (6.9  10.4 vs. 2.0  9.6, t = 2.15, P = 0.035) before and after
12 weeks of treatment were all signiﬁcantly greater in the Wu Ling
group than in the Placebo group (see Fig. 3).
3.5. Evaluation of tolerability
3.5.1. Adverse events
There were 13 (13/51) patients in the Wu Ling group and 16
(16/49) patients in the Placebo group who reported AEs. There
was no signiﬁcant difference between the two groups in the
Table 1
Characteristics of patients with epilepsy in the Wu Ling and the placebo groups.
Wu Ling group Placebo group P value
n = 51 n = 49
Age (year) mean  SD 40.1  13.4 45.2  14.7 0.07
Male: female 19:32 25:24 0.17
Educational degree (9 years: >9 years) 20:31 27:22 0.11
Marital status
(married:unmarried) (married/unmarried/divorced/widowed)
33:18 36:13 0.34
Height (cm) mean  SD (full/part/retired/unemployed/student) 164.5  8.1 164.5  7.2 0.98
Weight (kg) mean  SD 59.2  10.6 61.9  12.1 0.24
Duration of epilepsy (year) mean  SD 19.0  37.3 25.0  51.0 0.28
Seizure types (GTCS/CPS/SPS/sGTC/AS/ATS) 17:26:3:16:1:1 16:23:5:12:1:0 0.79
Etiologies n (%)
Brain injury 10 (19.6%) 8 (16.3%) 0.64
Intracranial infection 5 (9.8%) 1 (2.0%) 0.22
Birth asphyxia 4 (7.8%) 2 (4.1%) 0.69
Intracranial surgery 4 (7.8%) 11 (22.4%) 0.05
Unknown reasons 28 (54.9%) 27 (55.1%) 0.98
Seizure frequency in last 3 months mean  SD 1.85  2.37 2.33  3.53 0.33
NHS3 score mean  SD 11.6  7.0 10.7  7.0 0.53
History of SE (%) 7% 4% 0.17
AEDs used n (%)
CBZ 20 (39.2%) 22 (56.4%) 0.56
VPA 28 (54.9%) 30 (61.2%) 0.52
TPM 13 (25.5%) 14 (28.6%) 0.77
OXC 3 (5.9%) 3 (6.1%) 0.96
LTG 9 (17.6%) 5 (10.2%) 0.28
LEV 5 (9.8%) 3 (6.1%) 0.50
PB 3 (5.9%) 2 (4.1%) 0.68
PHT 2 (3.9%) 0 0.16
CZP 6 (11.8%) 8 (16.3%) 0.51
AEDs, antiepileptic drugs; GTCS, generalized tonic clonic seizure; CPS, complex partial seizure; SPS, simple partial seizure; sGTC, secondary generalized tonic clonic seizure;
AS, absence seizure; ATS, atonic seizure; NHS3, National Hospital Seizure Severity Scale; SE, status epilepticus; CBZ, carbamazepine; VPA, valproate; TPM, topiramate; OXC,
oxcarbazepine; LTG, lamotrigine; LEV, levetiracetam; PB, phenobarbital; PHT, phenytoin; CZP, clonazepam; SD, standard deviation.
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demonstrated that the patient was in the Placebo group and the
AE was not related to the Wu Ling Capsule treatment. The
symptoms of AEs can be categorized as follows by system organ
class: (1) general disorders: fatigue; (2) gastrointestinal dis-
orders: abdominal discomfort, elevated liver enzyme, constipa-
tion and increased saliva; (3) nervous system disorders:Fig. 2. (a) The total effective rate for depression in week 12 was signiﬁcantly greater in the
groups in weeks 2, 4 and 8, *P = 0.002. (b, c) HAMD total score was signiﬁcantly less whi
week 12, #P = 0.0367, *P = 0.001. HAMD, Hamilton Depression Rating Scale. DHST, the dreaminess, dizziness, feeling depressed; (4) respiratory, thoracic
and mediastinal disorders: anterior thoracic discomfort, palpita-
tion and ablepsy; (5) skin and subcutaneous tissue disorders: skin
rash and sneezing. The most frequently reported AEs were fatigue
(5%) and palpitations (4%). No signiﬁcant differences in the
above AEs were found between the Wu Ling and the Placebo
groups (see Table 3). Wu Ling group than in the Placebo group, which had no difference between the two
le DHST was signiﬁcantly greater in the Wu Ling group than in the Placebo group in
difference in HAMD score before and after treatment.
Table 2
Comparisons of R ratio and NHS3 score between the Wu Ling and the placebo
groups.
Items mean  SD (n) Wu Ling group Placebo group P value
R ratio 0.3  0.8 (36) 0.5  0.7 (39) 0.23
NHS3 score at baseline 11.6  7.0 (50) 10.7  7.0 (48) 0.53
NHS3 score at the end
of treatment
5.8  5.4 (39) 5.4  5.8 (42) 0.79
The difference in NHS3 score
before and after 12 weeks
of treatment
5.9  8.0 (39) 5.1  7.5 (42) 0.64
R ratio = (ﬁnal seizure frequency  baseline seizure frequency)/(ﬁnal seizure
frequency + baseline seizure frequency). NHS3, the National Hospital Seizure
Severity Scale; SD, standard deviation. R ratio represents changes in seizure
frequency of the baseline and the end of 12 weeks’ treatment. NHS3 score
represents seizure severity.
Fig. 3. The differences in total QOLIE-31 score, overall quality of life score and
seizure worry score before and after 12 weeks of treatment were signiﬁcantly
greater in the Wu Ling group than in the Placebo group, #P < 0.05, *P < 0.01. QOLIE-
31, the Quality of Life in Epilepsy Inventory-31.
Table 3
Adverse events by system organ class.
Events n (%) Wu Ling
group
Placebo
group
P value
(n = 51) (n = 49)
The number of AE 13 (25.5%) 16 (32.7%) 0.49
Any severe AE 0 (0) 1 (6.3%) 0.31
Any AE related to study drug 6 (46.2%) 12 (75%) 0.11
Any AE leading to discontinuation
of study drug
2 (15.4%) 3 (18.8%) 0.81
General disorders
Fatigue 4 (30.8%) 1 (6.3%) 0.08
Gastrointestinal disorders
Abdominal discomfort 2 (15.4%) 1 (6.3%) 0.42
Elevated liver enzyme 1 (7.7%) 0 0.26
Constipation 2 (15.4%) 1 (6.3%) 0.42
Increased saliva 1 (7.7%) 0 0.26
Nervous system disorders
Dreaminess 0 2 (12.5%) 0.19
Dizziness 0 1 (6.3%) 0.36
Feeling depressed 0 2 (12.5%) 0.19
Status epilepticus 0 1 (6.3%) 0.36
Respiratory, thoracic and mediastinal disorders
Anterior thoracic discomfort 1 (7.7%) 0 0.26
Palpitation 0 4 (25%) 0.05
Ablepsy 0 1 (6.3%) 0.36
Skin and subcutaneous tissue disorders
Skin rash 1 (7.7%) 0 0.26
Sneezing 1 (7.7%) 1 (6.3%) 0.88
AE, adverse event.
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No signiﬁcant changes in body weight, heart rate or blood
pressure were found in either the Wu Ling or the Placebo groups
after treatment. One patient had an elevated liver enzyme after
4 weeks’ treatment and was found to be infected with active
hepatitis B. She dropped out of the study and recovered after
treatment. Liver and renal functional variables (ALT, AST, gamma-
glutamyltransferase, blood urea nitrogen and creatinine), and the
abnormal rates of electrocardiogram (ECG) and electroencephalo-
gram (EEG) tests at baseline and at the end of treatment were all
compared between the Wu Ling and the Placebo groups, and the
results showed no differences (P > 0.05).
4. Discussion
Although depression is a common comorbidity of epilepsy, the
therapeutic methods are still limited and the evidence-based data
are lacking. Antidepressants such as SSRIs have the risk of
aggravating seizures, and several clinical trials are still open-label
studies [8,10]. Therefore, new medical therapies and more
randomized clinical trials are urgently needed. This study is one
of the few double-blind randomized placebo-controlled parallel
studies for patients with comorbidity of epilepsy and depression.
Xylaria nigripes had been used clinically to treat insomnia and
depression, and was known to have anticonvulsive effects in
animal studies, so it was utilized in this study for its possible
beneﬁts to alleviate depression and seizures simultaneously. This
study indicated that Xylaria nigripes could signiﬁcantly alleviate
depressive symptoms in patients with comorbidity of epilepsy and
depression compared with the placebo after at least 12 weeks’
treatment. The result of our study was accordance with a previous
clinical study in the general population with depression [20]. There
might be two reasons for the results that Xylarian nigripes
signiﬁcantly alleviated depressive symptoms in week 12 but not in
weeks 2, 4, 8. As indicated by Khan et al. [33], antidepressant
treatment always had placebo response which affected the clinical
trial outcome. The reason for no difference of total effective rate for
depression between the Wu Ling and the placebo groups in weeks
2, 4, 8 might be due to its placebo response. But the total effective
rate for depression had an increasing trend from week 2 to week
12, which indicated that Xylarian nigripes probably worked mildly
and slowly. A previous animal study also found the phenomenon
that Xylarian nigripes could have sedative effect only after 8 days
continuous treatment with high dose [22]. The relatively high
dropout rate in week 4 in this study might also due to the slow rate
at which Xylaria nigripes took effect.
There were no signiﬁcant changes in seizure frequency and
severity after 12 weeks of Xylaria nigripes treatment compared
with the placebo in this study. A previous animal study showed
that Xylaria nigripes could delay the kindling process and
ameliorate the learning deﬁcits of rats with penty1enetetrazole-
induced epilepsy [21]. However, to date (December 2014), there
have been no reports about the effects of Xylaria nigripes on
epileptic seizures in clinical studies. The results of WL-2010
indicated that Xylaria nigripes had no effect on epileptic seizures,
and they indirectly demonstrated that it did not present any risk of
aggravating seizures.
In addition, the total QOLIE-31 score, the overall quality of life
score and the seizure worry score were all higher in the Wu Ling
group than in the Placebo group in this study. We believed that the
effects of Xylaria nigripes on quality of life and seizure worry might
be secondary to the improvement of depressive symptoms in
patients with epilepsy. After treatment, there was also a decreasing
trend of the PSQI score in the Wu Ling group compared with the
Placebo group, but it had no statistical signiﬁcance in this study.
Previous studies showed that Xylaria nigripes could induce
W.-F. Peng et al. / Seizure 29 (2015) 26–3332sleepiness and maintain sleep time in insomnia patients [19], but
sleep disturbances such as insomnia and excessive daytime
sleepiness were both very common in patients with epilepsy
[34,35]. Daytime drowsiness had a particularly high prevalence
due to the side effects of AEDs. We thought that the negative
results of Xylaria nigripes on sleep quality in this study were
probably attributable to its ineffectiveness on daytime drowsiness
in patients with epilepsy. And there might also be some
confounding effects of clonazepam on sleep, which was used to
treat epileptic seizures in this study.
In this study, the total number of AE and percentage of AE
possibly related to study drug were both slightly higher in the
Placebo group than in the Wu Ling group. But the comparisons
both had no statistical signiﬁcance by chi-square test. We thought
these AEs might be confounded with somatic symptoms of
depression, which were hard to be distinguished by researchers.
One patient had a severe AE of SE, but she had uncontrolled
seizures 3–4 times every month at baseline, and was demonstrated
to be in the Placebo group by urgently unblinding. No signiﬁcant
differences of blood tests variables and abnormal rates of ECG and
EEG tests were found between the Wu Ling and the Placebo groups.
Therefore, it suggested that Xylaria nigripes was safe and well
tolerated by patients with epilepsy. In addition, as Xylaria nigripes
is a traditional Chinese medicine with multiple bioactive products,
its interaction with other drugs is not clear yet. There seemed no
obvious interactions between Xylaria nigripes and the AEDs from
clinical observations in this study.
One of the limitations of this study was that the sample size of
patients with comorbidity of epilepsy and depression was relatively
small. The most important reason for this might be related to the
HAMD being less sensitive to patients with epilepsy. Some authors
suggested that depressive symptoms in patients with epilepsy were
always untypical. According to Wiegartz et al. [36], only 30%
patients with epilepsy met the criteria of DSM-IV (Diagnostic and
Statistical Manual of Mental Disorders, 4th edition) for a current or
lifetime-to-date major depressive disorder. A study by Gandy et al.
indicated that HAMD had relatively poorer sensitivity (42%)
compared with the Neurological Depressive Disorders Inventory
for Epilepsy (NDDI-E) which had 84% sensitivity [37]. Another
reason was that many patients with comorbidity of epilepsy and
depression did not fully realize the negative inﬂuence of their
depression on their quality of life and were not willing to accept
treatment. In addition, stratiﬁcation to balance the different
antiepileptic medications in the Wu Ling and the Placebo groups
was not performed because of the relatively small sample size of
this study. However the percentages of all types of AEDs used at
baseline were compared and no signiﬁcant differences between the
Wu Ling and the Placebo groups were found.
5. Conclusions
In conclusion, Xylaria nigripes could be an acceptable treatment
to alleviate depressive symptoms in patients with epilepsy after at
least 12 weeks of treatment. It could also improve some aspects of
quality of life for patients with epilepsy without increasing the risk
of exacerbating epileptic seizures, and be well tolerated. Overall,
the WL-2010 study was still a preliminary small scale pilot study,
but its results could help to evaluate feasibility, time, adverse
events and effective size of a full-scale research project. A study
with better screening tools, a larger sample size and a longer
follow-up period would be expected in the future.
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